Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Merck’s first microbiology application and training lab in India
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
Mittal will be driving expansion of the provider network across India
Plant is part of the company's CAD $30 million capital investment in the site
LifeWell Raises USD 80M from OrbiMed to Build Large Scale Healthcare Delivery Platform with Full stack Diagnostics~
Researchers from Bar-Ilan University find that even in old age, feeling young can lower the risks of developing physical disability and morbidity
Subscribe To Our Newsletter & Stay Updated